Five-Year Analysis of Pivotal Reverse Trial Demonstrates Long-Term Clinical ... Reuters Throughout the REVERSE study, the benefits of CRT persisted, indicating that the device therapy reduces disease progression in patients with mildly symptomatic (New York Heart Association/NYHA-designated Class I and II) heart failure for at least 5 ... Medtronic study finds device slows heart-failure progression Medtronic: Study shows new therapy can reduce the size of enlarged hearts ... |
